Best deals to access real time data! |
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
CHART Trader
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| PhaseBio Pharmaceuticals Inc | PHAS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 3.23 | 0.00 | 0.00 | 0.00 | 3.23 | 08:30:36 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 3.05 | 3.45 | 0.40 | 11.59% | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.00 | USD |
PhaseBio Pharmaceuticals Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 92.70M | 28.70M | $ -23.85M | -4.62 | - | 28.53M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 4.00 | 0.60% |
PhaseBio Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PHAS Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.19 | 3.56 | 3.1234 | 3.30 | 213,695 | 0.04 | 1.25% |
| 1 Month | 4.10 | 4.12 | 3.06 | 3.44 | 266,409 | -0.87 | -21.22% |
| 3 Months | 5.10 | 5.44 | 3.06 | 4.33 | 368,329 | -1.87 | -36.67% |
| 6 Months | 11.22 | 14.27 | 3.06 | 5.85 | 251,703 | -7.99 | -71.21% |
| 1 Year | 3.28 | 17.52 | 2.56 | 8.40 | 263,715 | -0.05 | -1.52% |
| 3 Years | 5.00 | 17.52 | 2.55 | 8.19 | 246,741 | -1.77 | -35.4% |
| 5 Years | 5.00 | 17.52 | 2.55 | 8.19 | 246,741 | -1.77 | -35.4% |
PhaseBio Pharmaceuticals Description
| PhaseBio Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. The lead product candidate of the company is PB2452, which is a novel reversal agent for the antiplatelet drug ticagrelor, used for the treatment of patients experiencing major bleeding or those who require urgent surgery. It is also developing PB1046 which is a fusion protein for the treatment of pulmonary arterial hypertension. |
